Shares of Soleno Therapeutics, Inc. (Nasdaq: SLNO) soared over 300% in pre-market trading following the release of positive top-line results from Study C602. 

The study, which focused on the long-term treatment of Prader-Willi syndrome (PWS) using DCCR (Diazoxide Choline) Extended-Release tablets, met its primary endpoint with a highly statistically significant difference in the change from baseline in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Total Score for DCCR compared to the placebo (p=0.0022).

Additionally, secondary endpoints including Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) demonstrated notable trends, with the placebo group showing signs of worsening compared to the DCCR group over the randomized withdrawal period (p=0.08 and 0.09, respectively).
 
$SLNO was trading at $20.21 in pre-market, reflecting an increase of $15.78 (+356.21%).

In other news, BofA Securities has resumed coverage on Fisker Inc. (NYSE: FSR), a prominent electric vehicle manufacturer, with a Buy rating and a price target set at $8.

While $FSR closed at $5.31 on Monday, the assigned price target suggests a potential upside of $2.69 or approximately 50.66%, as per the financial advisory firm's analysis.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)